Dermata Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3525 Del Mar Heights Rd Ste 322, San Die...Phone Number
(858) 800-2543Website
www.dermatarx.comRevenue
-Stock Symbol
DRMAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis.Explore more
Dermata Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dermata Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Dermata Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Dermata Therapeutics is spiking on competitors!
Dermata Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Dermata Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Dermata Therapeutics
Click to see if Dermata Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Dermata Therapeutics has new funding data
Earning: See what the market has to say on Dermata Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Dermata Therapeutics
Compare insights from companies similar to Dermata Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dermata Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dermata Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dermata Therapeutics.
Dermata Therapeutics financials insights
Gather financial insights about Dermata Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$6.2M
Dermata Therapeutics Tech Stack
A closer look at the technologies used by Dermata Therapeutics
Most Recent Scoops
Project
Dermata Therapeutics has announced plans to launch a once-weekly over-the-counter acne kit in mid-2024, combining its Spongilla technology with OTC-approved acne products. The company claims the product will offer faster treatment effects and better tolerability compared to existing OTC options.
Project
Dermata Therapeutics has announced plans to initially launch its new acne treatment kit direct-to-consumer in the US market, targeting 50 million people with acne. The company stated there are no regulatory hurdles as the kit combines an approved OTC product with their Spongilla product.
Project
Dermata Therapeutics has conducted market research revealing that approximately 70% of patients explore over-the-counter (OTC) acne products for up to a year before consulting a dermatologist. The study also found that while the OTC acne market is growing, the prescription acne market is declining due to insurance and reimbursement issues.
Project
Dermata Therapeutics has announced a strategic shift to over-the-counter (OTC) products, citing three key drivers: speed to market with no FDA approval required, reduced development costs, and improved accessibility for patients through direct-to-consumer sales.
Project
Dermata Therapeutics News & Media
Dermata Therapeutics (DRMA) prices up to $12.4M private placement - Stock Titan
Dermata sells 2M shares and warrants at $2.04 in a private deal, raising $4.1M now and potentially $8.3M more if new warrants are fully exercised.Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The ...
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," ...Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comDermata Secures $6.2M Financing Through Strategic Warrant Exercise | DRMA Stock News
Biotech firm secures immediate $6.2M through warrant restructuring, strengthening cash position for clinical trials and R&D pipeline. Full investment implications inside.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Dermata Therapeutics
Sign Up For FreeTo access detailed company insights
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acn... Read More
